Literature DB >> 35586420

Small-Molecule Inhibitor of the Oncogenic KRASG12C Mutant for the Treatment of Currently Incurable Cancer.

Robert B Kargbo1.   

Abstract

Entities:  

Year:  2022        PMID： 35586420      PMCID： PMC9109474          DOI： 10.1021/acsmedchemlett.2c00152

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  6 in total

Review 1.  Drugging "undruggable" genes for cancer treatment: Are we making progress?

Authors:  Michael J Duffy; John Crown
Journal:  Int J Cancer       Date:  2020-08-07       Impact factor: 7.396

Review 2.  Drugging the Next Undruggable KRAS Allele-Gly12Asp.

Authors:  Qinheng Zheng; D Matthew Peacock; Kevan M Shokat
Journal:  J Med Chem       Date:  2022-02-15       Impact factor: 7.446

Review 3.  Resistance looms for KRAS G12C inhibitors and rational tackling strategies.

Authors:  Junmin Zhang; Juanhong Zhang; Qing Liu; Xing-Xing Fan; Elaine Lai-Han Leung; Xiao-Jun Yao; Liang Liu
Journal:  Pharmacol Ther       Date:  2021-12-03       Impact factor: 12.310

Review 4.  Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants.

Authors:  Marco H Hofmann; Daniel Gerlach; Sandra Misale; Mark Petronczki; Norbert Kraut
Journal:  Cancer Discov       Date:  2022-04-01       Impact factor: 38.272

Review 5.  Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies.

Authors:  Anne-Laure Désage; Camille Léonce; Aurélie Swalduz; Sandra Ortiz-Cuaran
Journal:  Front Oncol       Date:  2022-02-16       Impact factor: 6.244

Review 6.  Targeting KRAS mutant lung cancer: light at the end of the tunnel.

Authors:  Matthias Drosten; Mariano Barbacid
Journal:  Mol Oncol       Date:  2022-01-18       Impact factor: 6.603
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.